Table 2. Receptor status and phenotype based on biopsy in 21 cases, on whole-mastectomy specimen in 16 cases, and on the combination of whole-mastectomy specimen and biopsy.
|
Receptor status |
||||||||
|---|---|---|---|---|---|---|---|---|
| ER+ | ER− | PR+ | PR− | HER2+ | HER2− | Ki67+(⩽14%) | KI67−(>14%) | |
| Biopsy | 14/21 | 7/21 | 12/21 | 9/21 | 10/21 | 11/21 | 12/21 | 9/21 |
| Mastectomy | 11/16 | 5/16 | 9/16 | 7/16 | 6/16 | 10/16 | 10/16 | 6/16 |
|
Phenotype |
||||
|---|---|---|---|---|
| Luminal A | Luminal B | Luminal HER2 | HER2 Enriched | |
| Biopsy | 3/21 | 8/21 | 3/21 | 7/21 |
| Mastectomy | 5/16 | 5/16 | 1/16 | 5/16 |
| Biopsy plus Mastectomy | 6/21 | 5/21 | 3/21 | 7/21 |
Abbreviations: ER=oestrogen receptor expression; HER2=human epidermal growth factor receptor 2; PR=progesterone receptor expression; Ki67=antigen Ki-67.